Bhrigu Bhanupriya, Sharma Shikha, Kumar Nitin, Banik Bimal Krishna
Department of Pharmaceutical Science, Lords University, Alwar, 301028, Rajasthan, India.
Department of Mathematics and Natural Sciences, College of Sciences and Human Studies, Prince Mohammad Bin Fahd University, Al Khobar, Kingdom of Saudi Arabia.
Curr Diabetes Rev. 2025;21(6):12-31. doi: 10.2174/0115733998290606240521113832.
Diabetic neuropathy, also known as diabetic peripheral sensorimotor neuropathy (DPN), is a consequential complexity of diabetes, alongside diabetic nephropathy, diabetic cardiomyopathy, and diabetic retinopathy. It is characterized by signs and symptoms of peripheral nerve damage in diabetes patients after ruling out other causes. Approximately 20% of people with diabetes are affected by this painful and severe condition. The development of diabetic neuropathy is influenced by factors such as impaired blood flow to the peripheral nerves and metabolic issues, including increased polyol pathway activation, myo-inositol loss, and nonenzymatic glycation. The present review article provides a brief overview of the pathological changes in diabetic neuropathy and the mechanisms and types of DPN. Various diagnostic tests and biomarkers are available to assess nerve damage and its severity. Pharmacotherapy for neuropathic pain in diabetic neuropathy is complex. This review will explore current treatment options and potential future developments to improve the quality of life for patients suffering from diabetic neuropathy.
糖尿病性神经病变,也称为糖尿病周围感觉运动神经病变(DPN),是糖尿病的一种严重并发症,与糖尿病肾病、糖尿病心肌病和糖尿病视网膜病变并存。其特征是在排除其他病因后,糖尿病患者出现周围神经损伤的体征和症状。约20%的糖尿病患者受这种疼痛且严重的病症影响。糖尿病性神经病变的发展受多种因素影响,如外周神经血流受损以及代谢问题,包括多元醇途径激活增加、肌醇流失和非酶糖基化。本综述文章简要概述了糖尿病性神经病变的病理变化以及DPN的机制和类型。有多种诊断测试和生物标志物可用于评估神经损伤及其严重程度。糖尿病性神经病变中神经性疼痛的药物治疗很复杂。本综述将探讨当前的治疗选择以及未来可能的发展方向,以改善糖尿病性神经病变患者的生活质量。